<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00996515</url>
  </required_header>
  <id_info>
    <org_study_id>INST 0710C</org_study_id>
    <secondary_id>NCI-2011-02646</secondary_id>
    <nct_id>NCT00996515</nct_id>
  </id_info>
  <brief_title>A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies</brief_title>
  <official_title>A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New Mexico Cancer Care Alliance</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New Mexico Cancer Care Alliance</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To document the toxicities, and reversibility of toxicities, of this regimen of&#xD;
      5-azacytidine (azacitidine) and erlotinib (erlotinib hydrochloride).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine any potential anti-tumor effects, as determined by the objective tumor&#xD;
      response (complete and partial responses), clinical benefit (complete and partial responses,&#xD;
      and clinical benefit), the time to tumor response, the time to tumor progression, and the&#xD;
      overall survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive azacitidine intravenously (IV) over 10-40 minutes or subcutaneously (SC) on&#xD;
      days 1 and 15, days 1-2 and 15-16, days 1-3 and 15-17, or days 1-4 and 15-18. Patients also&#xD;
      receive erlotinib hydrochloride orally (PO) daily on days 1-21. Courses repeat every 28 days&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 28 days and then every 3&#xD;
      months for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality and quantity of adverse events due to administration of erlotinib + 5-azacytidine, as therapy for the treatment of advanced or metastatic cancer.</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Advanced Solid Tumor Malignancies</condition>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 150mg/day PO Day 1-28 and Vidaza 100mg/m2/day SQ Day 1-4 and 15-18</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 200 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day SQ 1-4 and 15-18</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1-3 and 15-17</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1-2 and 15-16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1 and 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-azacytidine, erlotinib</intervention_name>
    <description>Erlotinib 150 mg PO daily, days 1-8, and 15-22 5-Azacytidine 75 mg/m2/day, IV days 1 and 15</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <other_name>Erlotinib :- Tarceva™ (OSI-774)</other_name>
    <other_name>Vidaza (5-azacytidine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib PO and Vidaza IV</intervention_name>
    <description>Patients enrolled to 1 of 5 cohorts, with varying drug doses and dose scheduling.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must fulfill all of the following criteria to be eligible for study entry:&#xD;
&#xD;
          -  Those who will be eligible will be all patients with non-hematologic neoplasms&#xD;
             (lymphomas, leukemias, myeloma, myelodysplasia, or myeloproliferative syndromes) who&#xD;
             have disease which has been previously treated and/or for which there is no acceptable&#xD;
             standard treatment regimen available, and cannot be treated definitively with either&#xD;
             surgery or radiotherapy. All will be appropriate candidates for treatment, and are not&#xD;
             candidates for treatment with protocols of higher priority. All patients should have&#xD;
             an ECOG/Zubrod/SWOG performance status of &lt;2 at the time of the initiation of therapy,&#xD;
             adequate end-organ function, no severe comorbid disease, and ability to provide&#xD;
             informed consent.&#xD;
&#xD;
        Other Eligibility Criteria:&#xD;
&#xD;
          -  Signed Informed Consent&#xD;
&#xD;
          -  ECOG/Zubrod/SWOG Performance Status &lt;2 (Karnofsky Performance Status &gt; 70%)&#xD;
&#xD;
          -  Life expectancy &gt; 8 weeks&#xD;
&#xD;
          -  Male or female' age &gt;18 years&#xD;
&#xD;
          -  Patients of childbearing potential must be using an effective means of contraception.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test prior to&#xD;
             azacitidine treatment.&#xD;
&#xD;
          -  Histologic diagnosis of a solid tumor malignancy that is advanced and cannot be&#xD;
             treated adequately by radiotherapy or surgery; or metastatic disease&#xD;
&#xD;
          -  Baseline laboratory values (bone marrow, renal, hepatic):&#xD;
&#xD;
               -  Adequate bone marrow function:&#xD;
&#xD;
               -  Absolute neutrophil count &gt;1000/µL&#xD;
&#xD;
               -  Platelet count &gt;100'000/µL&#xD;
&#xD;
               -  Renal function:&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 x ULN&#xD;
&#xD;
               -  Hepatic function:&#xD;
&#xD;
          -  Bilirubin &lt;1.5x normal&#xD;
&#xD;
               -  Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST])&#xD;
                  or serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT])&#xD;
                  levels &lt;=2 x ULN&#xD;
&#xD;
               -  Serum calcium &lt; 12 mg/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients meeting any of the following criteria are ineligible for study entry:&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Myocardial infarction or ischemia within the 6 months before Cycle 0' Day 0&#xD;
&#xD;
          -  Uncontrolled' clinically significant dysrhythmia&#xD;
&#xD;
          -  Prior radiotherapy to an indicator lesion unless there is objective evidence of tumor&#xD;
             growth in that lesion&#xD;
&#xD;
          -  Uncontrolled metastatic disease of the central nervous system&#xD;
&#xD;
          -  Sensitivity to erlotinib, 5-azacytidine or mannitol&#xD;
&#xD;
          -  Advanced hepatic tumors&#xD;
&#xD;
          -  Radiotherapy within the 2 weeks before Cycle 1' Day 1&#xD;
&#xD;
          -  Surgery within the 2 weeks before Cycle 1' Day 1&#xD;
&#xD;
          -  Any co morbid condition that' in the view of the attending physician' renders the&#xD;
             patient at high risk from treatment complications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie E Bauman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>October 14, 2009</study_first_submitted>
  <study_first_submitted_qc>October 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2009</study_first_posted>
  <last_update_submitted>April 30, 2013</last_update_submitted>
  <last_update_submitted_qc>April 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumor Malignancies</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>Vidaza</keyword>
  <keyword>Tarceva</keyword>
  <keyword>5-azacytidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

